Teva, Lundbeck Announce European Approval for Azilect

Teva Pharmaceutical Industries and H. Lundbeck A/S has announced that the European Commission issued a marketing authorization valid throughout the European Union for Azilect (rasagiline 1 mg, once daily), for the treatment of Parkinson's disease (PD) both as monotherapy in patients with early PD and as adjunct treatment in moderate-to-advanced disease.

The companies intend to market the product in various countries across Europe during the second quarter 2005.